Q-omics provides the consensus-scored GAPDHP2 profile across patient tissues and cancer cell-line models. GAPDHP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, GAPDHP2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, GAPDHP2 RNA expression shows 13,980 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUSC, KIRC, and THYM as cancer lineages where GAPDHP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP2 survival associations across molecular data types. GAPDHP2 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP2 RNA expression–survival associations across cancer types. High GAPDHP2 expression shows unfavorable associations in KIRP, LGG, LIHC and SARC, but favorable associations in LUSC and LAML. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for GAPDHP2 RNA expression.
This table summarizes GAPDHP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP2 shows higher tumor expression in KIRC, KIRP, COAD, HNSC, LUSC and LUAD. The KIRC box plot shows higher GAPDHP2 RNA expression in tumor versus normal tissue (log2 FC = +0.597, t-test p < 0.001).
This table shows molecular features associated with GAPDHP2 in patient tissues and cancer cell lines. In patient samples, GAPDHP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
